1-877-439-2744 Motherisk Helpline
1-800-436-8477 Morning Sickness
1-877-327-4636 Alcohol and Substance
1-866-937-7678 Exercise in Pregnancy
1-888-246-5840 HIV and HIV Treatment
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Current Studies at Motherisk
The Safety of Diclectin in Breastfeeding
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Alcohol Use during Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Cancer in Pregnancy
The occurrence of cancer during pregnancy is a rare and challenging event. But as more and more women delay child-bearing until later in life, the rate of cancer in pregnancy is expected to rise. New clinical practice guidelines have been prepared by the Chemotherapy During Pregnancy Working Group and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada.
The lead author of the Guidelines is Dr. Gideon Koren, Director of the Motherisk Program. The guidelines were published in March 2013 and are available online in Acrobat format at http://sogc.org/guidelines/documents/gui288CPG1303E.pdf.
Information is also available in Cancer in Pregnancy and Lactation: The Motherisk Guide. Published in 2011, this book contains evidence-based information needed to address the complex issues of maternal diagnosis, management, treatment, prognosis and long-term impact on the unborn child. Co-edited by recognized experts in the field with over 25 years' experience, this comprehensive volume is essential reading for all maternal-fetal medicine physicians, obstetricians, neonatologists, oncologists, and pharmacologists.